European Medicines Agency accepts Marketing Authorisation Application for cenobamate for the adjunctive treatment of focal onset seizures in adults

Cenobamate is a sodium channel blocker, with a binding site different from that of classical sodium channel blockers. The application is based on results from 2 global RCTs and an open-label safety study enrolling >1,900 adults with uncontrolled focal-onset seizures.


Biospace Inc.